Shanghai Keqi Pharmaceutical Technology

Shanghai Keqi Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery of novel small molecule therapeutics. The firm focuses on high-impact therapeutic areas, particularly oncology and metabolic disorders, by targeting specific biological pathways such as the DNA damage response. Its flagship candidate, KQ-A101, is a potent and selective inhibitor of Ubiquitin-specific protease 1 (USP1) currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. Keqi Pharma aims to leverage its internal research expertise to develop a robust pipeline of precision medicines. The company is backed by leading healthcare investors, including HighLight Capital and Sherpa Healthcare Partners.